Ago2 Antibody, Brachyury Antibody, Brn3A Antibody, Cd45Ro Antibody, Cdk5 Antibody, Erg Antibody, Foxa2 Antibody, Gerbil, Goat, Guinea, Hamster, Horse, Influenza, Insect, Jmjd3 Antibody, Kangaroo, Killifish, Klf2 Antibody, Lkb1 Antibody, Mobp Antibody, Rabbit, Raccoon, Rat, Tbp Antibody, Zeb2 Antibody

Genetic landscape of congenital disorders in patients from Southeast Asia: results from sequencing using a gene panel for Mendelian phenotypes

Goal: To check the utility and diagnostic yield of a medical-exome gene panel for figuring out pathogenic variants in Mendelian problems.

 

Strategies: Subsequent-generation sequencing was carried out with the TruSight One gene panel (concentrating on 4813 genes) adopted by MiSeq sequencing on 216 sufferers who offered with suspected genetic problems as assessed by their attending physicians.

 

Outcomes: There have been 56 pathogenic and 36 possible pathogenic variants throughout 57 genes recognized in 87 sufferers. Causal mutations have been extra prone to be truncating and from sufferers with a previous scientific analysis. One other 18 promising variants want additional analysis for extra proof to satisfy the requirement for potential improve to pathogenic. Forty-five of the 92 clinically important variants have been novel.

 

Conclusion: The 40.3% constructive yield compares favourably with related research utilizing both this panel or complete exome sequencing, demonstrating that enormous gene panels may very well be various to complete exome sequencing for fast genetic affirmation of Mendelian problems.

 

Affiliation between Main Healthcare and Medical Expenditures in a Context of Hospital-Oriented Healthcare System in China: A Nationwide Panel Dataset, 2012-2016

 

Whole well being expenditure in China has grown significantly since a brand new spherical of well being system reform was enacted in 2009. Researchers have proven that strengthening main healthcare could also be an choice for international locations to resolve the speedy enlargement of their medical expenditures. This research was designed to discover the affiliation between the energy of main healthcare and medical expenditures, within the context of the hospital-oriented healthcare system in China.

A longitudinal ecological research was carried out utilizing a 5-year panel dataset of 27 provinces in mainland China. The linear combined results regression mannequin was used to evaluate the consequences of main healthcare-related metrics on medical expenditures, controlling for the provincial degree specialty care doctor provide and socio-economic parameters.

The entire three main healthcare-related metrics confirmed damaging associations with the 2 medical expenditure parameters. Main care physicians per 10,000 inhabitants was considerably related to the per capita hospital medical expenditures (p < 0.05), and the proportion of public well being expenditure in complete well being expenditure was considerably related to each per capita complete medical expenditure and per capita hospital medical expenditures (p < 0.01 for each).

Our research discovered damaging associations between the first healthcare capability and medical expenditure within the context of hospital-oriented healthcare techniques in China, including to the earlier proof that main healthcare might play a constructive function in decreasing medical expenditure. Insurance policies on rising the first care doctor provide and the general public share of complete well being expenditure must be carried out to strengthen the first healthcare system. With the gradual advance of medical reform and the coverage inclination to main healthcare, this may play a extra essential function in controlling the speedy progress of medical expenditure.

expressionpathology
expressionpathology

Mechanical Properties of Nook Joints Fabricated from Honeycomb Panels with Double Arrow-Formed Auxetic Cores

The event of each gentle and powerful wood-derived supplies is an fascinating analysis space, significantly by way of usability in, e.g., furnishings constructions. Honeycomb panels being present trade commonplace are comparatively thick (32 mm and 40 mm), thus their attractiveness in designing furnishings is proscribed.

In just a few research, it has been proven that honeycomb panels with paper cores are characterised by unsatisfactory mechanical properties, particularly when the composite thickness is lower than 20 mm. From the literature, it is usually evident that mechanical properties may be improved by introducing auxetic options into the core construction.

Though it’s a idea with nice potential, there are just a few research coping with honeycomb panels with auxetic cores fabricated from paper. Moreover, there’s no analysis on the nook joints constituted of such materials. For that reason, the goal of the research was to check the bending habits of the nook adhesive joints fabricated from honeycomb panels with double arrow-shaped auxetic cores.

Inside the analysis, the core cell was adopted based mostly on literature and preliminary research, paper auxetic cores have been produced by means of the designed and 3d printed gadget, and joints stiffness and energy have been calculated analytically based mostly on the experiment outcomes.

Evaluated nook joints stiffness, each in compression and rigidity take a look at, is larger for samples fabricated from panels with designed auxetic cores. Surprisingly, within the analyzed vary of elasticity, it was statistically proved that the values of joint stiffness coefficient Ok didn’t range considerably between in contrast joints pairs.

The impact of the presence of kids on grownup smoking behaviour: empirical proof based mostly on China household panel research

Background: Regardless of numerous research linking household and marriage elements with well being behaviour, the consequences of kids on the well being behaviour of oldsters are nonetheless understudied. This research explored the affiliation between the presence of kids and adults’ smoking behaviours.

 

Strategies: This research used panel information from the China Household Panel Research 2010 and 2012, and the info set included 23,157 households and 45,513 adults. Logistic regression was carried out to analyse the affiliation of the presence of kids on adults’ smoking behaviours. Subgroup regression was used to look at heterogeneous results.

 

Outcomes: Full pattern regressions confirmed that the variety of youngsters was considerably inversely related to smoking behaviour (OR = 0.93; 95% 0.90-0.96). Additional subsample regression finds that such impact is just important among the many high-education group (OR = 0.92; 95% 0.87-0.97), high-skill staff (OR = 0.89; 95% 0.80-0.99) and {couples} who had an age hole better than 2 years (OR = 0.91; 95% 0.88-0.95).

 

Conclusions: Our findings affirm the existence of the upward intergenerational impact of the presence of kids on adults’ smoking behaviour in China. Nonetheless, such results will not be equal throughout all demographic traits. Future analysis might discover different elements of the upward mechanism and doable pathways for a stronger impact. In resource-poor areas, concentrating on cessation actions at those that have youngsters at an early age could also be an efficient technique.

Mouse Monoclonal Anti-Gardasil vaccine L1s (Human Papilloma Virus/HPV6+11+16+18 late proteins) antiserum control for ELISA

HPV618L13-S 1 ml
EUR 562.8

Rabbit Anti-Gardasil vaccine (merck) antiserum (Human Papilloma Virus 16+18 (HPV16/18) late proteins L1 (HPV16+18L1) control for ELISA

HPV16181-S 500 ul
EUR 562.8

Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgG antiserum negative control

970-360-01N 1 ml
EUR 196.8

Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgG antiserum positive control

970-360-02P 1 ml
EUR 270

Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgM antiserum negative control

970-370-01N 1 ml
EUR 196.8

Human Anti-Merozoite surface protein-1 (MSP-1; P. falciparum/malaria vaccine) IgM antiserum positive control

970-370-02P 1 ml
EUR 270

Labcold Gel Pack for Vaccine Transport Bag - EACH

REF4120 EACH
EUR 5.92

Recombinant flagellin FlicC vaccine adjuvant (TLR5 agonist); vaccine adjuvant

AV-7010-50 50 ug
EUR 1074

Bordetella bronchiseptica proteins (inactivated vaccine for dog) for ELISA

BBV15-N-100 100 ug
EUR 343.2

Labcold Rigid Cool Block for Vaccine Transport Bag - EACH

REF4122 EACH
EUR 22.37

Saponin Vaccine Adjuvant

VAdv-Ly0009 1 g
EUR 1314
Description: Saponin Vaccine Adjuvant, plant-based vaccine adjuvant.

Rabbit Anti-West Nile Virus vaccine (WNV, Recombitek/DNA vaccine) antiserum

WNV13-S 100 ul
EUR 548.4

SARS-CoV-2 Spike RBD ELISA Kit (For Vaccine Development)

RAS-A050 96tests
EUR 631.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike Protein RBD is urgently needed to accelerate the development of COVID-19 vaccines.

Rabies virus Glycoprotein G ELISA Kit (For Vaccine Development)

RAS-A167 96tests
EUR 631.3
Description: Rabies virus (RABV), scientific name Rabies lyssavirus, is a deadly neurotropic virus that causes rabies in humans and animals. Rabies virus has an extremely wide host range and its transmission most often occur through the saliva of animals. Without intervention prior to disease progression, rabies has the highest case fatality of any infectious disease. RABV contains a single-stranded negative-sense R genome that encodes five structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and R-dependent R polymerase (L). Among these viral proteins, the RABV glycoprotein (RABV-G) is a pivotal player mediating virus entry and the major target of neutralizing antibodies, thus a key factor for vaccine and drug design.A rapid and effective assay kit detecting the levels ofRABV-G is urgently needed to accelerate the development of RABV vaccines.

Peanut Oil vaccine adjuvant

AV-5010-50 50 ml
EUR 270

Mineral Oil vaccine adjuvant

AV-5020-50 50 ml
EUR 270

SARS-CoV-2 Spike Protein ELISA Kit (For Vaccine Development)

RAS-A039 96tests
EUR 631.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

HS15 Kolliphore vaccine adjuvant

AV-6010-100 100 g
EUR 343.2

Labcold Trolley for Use with 20L/30L Vaccine Transport Bags - EACH

REF4118 EACH
EUR 286.42

Calcium phosphate vaccine adjuvant

AV-1020-100 100 ml
EUR 262.8

Pam2CSK4 vaccine adjuvant; Biotin conjugate

AV-9020-B 1 mg
EUR 489.6

Pam2CSK4 vaccine adjuvant; Biotin conjugate

AV-9020-B-100 100 ug
EUR 196.8

Mannide monooleate vaccine adjuvant

AV-5030-5 5 g
EUR 196.8

Pam2CSK4 vaccine adjuvant, unlabeled

AV-9020-1 1 mg
EUR 489.6

Pam3CSK4 vaccine adjuvant, unlabeled

AV-9025-1 1 mg
EUR 343.2

SARS-CoV-2 Spike RBD (XBB.1.5) ELISA Kit (For Vaccine Development)

RAS-A146 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike RBD is urgently needed to accelerate the development of COVID-19 vaccines.

RWJ 21757 Synthetic vaccine adjuvant

AV-9010-1 1 mg
EUR 196.8

RWJ 21757 Synthetic vaccine adjuvant

AV-9010-5 5 mg
EUR 343.2

Standard Nutrient Broth (H.S. Vaccine

M116-500G 1 unit
EUR 24.58
Description: Standard Nutrient Broth (H.S. Vaccine

SARS-CoV-2 Spike Trimer (XBB.1.5) ELISA Kit (For Vaccine Development)

RAS-A145 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike Trimer is urgently needed to accelerate the development of COVID-19 vaccines.

SARS-CoV-2 Spike Trimer (XBB.1) ELISA Kit (For Vaccine Development)

RAS-A149 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike Trimer is urgently needed to accelerate the development of COVID-19 vaccines.

Pam3CSK4 vaccine adjuvant; FITC labelled

AV-9025-F 100 ug
EUR 416.4

Pertussis Toxin B.Pertussis, vaccine grade

AV-9130-50 50 ug
EUR 634.8

SARS-CoV-2 Spike S1 (B.1.1.529) Specific ELISA Kit (For Vaccine Development)

RAS-A170 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike S1 is urgently needed to accelerate the development of COVID-19 vaccines.

Peptidoglycan (S. aureus); vaccine adjuvant

AV-7045-25 25 mg
EUR 1220.4

Peptidoglycan (S. aureus); vaccine adjuvant

AV-7045-5 5 mg
EUR 343.2

Labcold Vaccine Transport Bag 3L - EACH

REF4110 EACH
EUR 189

SARS-CoV-2 Spike RBD (B.1.1.529) Specific ELISA Kit (For Vaccine Development)

RAS-A082 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

SARS-CoV-2 Spike RBD (B.1.617.2) Specific ELISA Kit (For Vaccine Development)

RAS-A092 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

Pam3CSK4 vaccine adjuvant; Biotin labelled

AV-9025-B 100 ug
EUR 416.4

Labcold Vaccine Transport Bag 10L - EACH

REF4112 EACH
EUR 249.75

Labcold Vaccine Transport Bag 20L - EACH

REF4114 EACH
EUR 310.5

Labcold Vaccine Transport Bag 30L - EACH

REF4116 EACH
EUR 429.3

B.Q. Vaccine HiCynth™ Medium (Thioglycol

MCD462-500G 1 unit
EUR 35.17
Description: B.Q. Vaccine HiCynth™ Medium (Thioglycol

Core Panel Multi-Tumor control slides, set of 5

TS900 Set of 5
EUR 145
Description: Core Panel Multi-Tumor control slides, set of 5

Core Panel Multi-Tumor control slides, set of 25

TS900-25 Set of 25
EUR 425
Description: Core Panel Multi-Tumor control slides, set of 25

SARS-CoV-2 Spike Trimer (B.1.617.2) Specific ELISA Kit (For Vaccine Development)

RAS-A055 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

SARS-CoV-2 Spike Trimer (B.1.1.529) Specific ELISA Kit (For Vaccine Development)

RAS-A081 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

SARS-CoV-2 Spike Trimer (BA.4) Specific ELISA Kit (For Vaccine Development)

RAS-A124 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

SARS-CoV-2 Spike Trimer (BA.5) Specific ELISA Kit (For Vaccine Development)

RAS-A125 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

SARS-CoV-2 Spike RBD (Wild Type) Specific ELISA Kit (For Vaccine Development)

RAS-A116 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

Varicella Zoster Virus Glycoprotein E (VZV gE) ELISA Kit (For Vaccine Development)

RAS-A135 96tests
EUR 631.3
Description: Varicella-zoster virus (VZV) the etiologic agent of chickenpox and herpes zoster [HZ], is highly contagious and still endemic worldwide. Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of Immunogenicity in the development of VZV vaccine.Therefore,It's helpful to develop the Varicella Zoster Virus Glycoprotein E (VZV gE) ELISA Kit to quantitative detection the VZV gE antigen in vaccine samples during the manufacture and quality control of vaccine development.

HRSV (A) Pre-Fusion glycoprotein F0 Specific ELISA Kit (For Vaccine Development)

RAS-A163 96tests
EUR 845.3
Description: Respiratory syncytial virus (RSV) is a highly contagious virus causing severe infection in infants and the elderly. Various approaches are being used to develop an effective RSV vaccine. The RSV fusion (F) subunit, particularly the cleaved trimeric pre-fusion F, is one of the most promising vaccine candidates under development.A rapid and effective assay kit detecting the levels of HRSV (A) Pre-Fusion glycoprotein F0 is urgently needed to accelerate the development of RSV vaccines.

HRSV (A) Post-Fusion glycoprotein F0 Specific ELISA Kit (For Vaccine Development)

RAS-A169 96tests
EUR 845.3
Description: Most in vitro RSV neutralizing antibodies in human sera are directed against the prefusion conformation, but due to its instability the prefusion conformation has a propensity to prematurely refold into the stable postfusion conformation, both in solution and on the surface of the virions. An RSV F protein that has both high expression levels and maintains a stable prefusion conformation would, therefore, be a promising subunit vaccine candidate against RSV. To facilitate the RSV-related research, drug trials and vaccine development,a rapid and effective assay kit detecting the specific levels of HRSV (A) Post-Fusion glycoprotein F0 is urgently needed to accelerate the development of RSV vaccines.

Breast Panel Multi-Tumor control slides, set of 5

TS901 Set of 5
EUR 145
Description: Breast Panel Multi-Tumor control slides, set of 5

Breast Panel Multi-Tumor control slides, set of 25

TS901-25 Set of 25
EUR 395
Description: Breast Panel Multi-Tumor control slides, set of 25

Mouse Anti-Her2 Protein (ECD) ELISA kit for Her2 vaccine, 96 tests, Quantitative

200-620-HRH 1 Kit
EUR 927.6

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to West Nile Virus vaccines (WNV-ENV/NS1/prM) vaccine by ELISA

910-360-CUX Custom Ask for price

HER2 peptide, (369 ?377), E75 vaccine candidate

HER2-369-P 5 mg
EUR 416.4

HER2 peptide, (654 ? 662), GP2 vaccine candidate

HER2-654-P 5 mg
EUR 416.4

SARS-CoV-2 Spike Trimer (Wild Type) Specific ELISA Kit (For Vaccine Development)

RAS-A115 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

Purified Cholera Toxin protein; vaccine grade

AV-9135-1000 1 mg
EUR 781.2

Purified Cholera Toxin protein; vaccine grade

AV-9135-500 500 ug
EUR 416.4

SARS-CoV-2 Spike RBD (BA.4 & BA.5) Specific ELISA Kit (For Vaccine Development)

RAS-A126 96tests
EUR 845.3
Description: The newly identified Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has posed a serious threat to human health. A rapid and effective assay kit detecting the levels of SARS-CoV-2 Spike protein is urgently needed to accelerate the development of COVID-19 vaccines.

Zika Virus (ZIKV) Envelop protein ELISA kit for vaccine testing, 48 tests, Quantitative

RV-403001-ENV-48 1 Kit
EUR 1000.8

Human Anti-Her2 Protein (ECD) IgG ELISA kit for Her2 vaccine, 96 tests, Quantitative

200-600-HRH 1 Kit
EUR 927.6

Human Anti-Her2 Protein (ECD) IgM ELISA kit for Her2 vaccine, 96 tests, Quantitative

200-610-HRM 1 Kit
EUR 927.6

Mouse Anti-Her2 Protein (ECD) IgM ELISA kit for Her2 vaccine, 96 tests, Quantitative

200-630-HRM 1 Kit
EUR 927.6

Vet-SAP Vaccine adjuvant, (EU GMP grade) >95%;

AV-4020-100 100 mg
EUR 196.8

Vet-SAP Vaccine adjuvant, (EU GMP grade) >95%;

AV-4020-1000 1 g
EUR 634.8

Control Animal Genomic DNA Panel, Set of any 5 species

G-005 5X0.025mg
EUR 720

Control Animal Genomic DNA Panel, Set of any 10 species

G-010 10x0.025mg
EUR 1193

Human Anti-Human Chorionic Gonadotropin (HCG) IgG ELISA kit for HCG Vaccine, 96 tests

500-300-HHG 1 kit
EUR 854.4

Mouse Anti-Human Chorionic Gonadotropin (HCG) IgG ELISA kit for HCG Vaccine, 96 tests

500-330-HRG 1 kit
EUR 854.4

Rabbit Anti-Human Chorionic Gonadotropin (HCG) IgG ELISA kit for HCG Vaccine, 96 tests

500-320-HMG 1 kit
EUR 854.4

Zika Virus NS1 (ZIKV-NS1) protein ELISA kit for vaccine testing, 96 tests, Quantitative

RV-403301-NS1-48 1 Kit
EUR 1000.8

Complete Freund?s Adjuvant (CFA);vaccine adjuvant

AV-3010-10 10 ml
EUR 343.2

Complete Freund?s Adjuvant (CFA);vaccine adjuvant

AV-3010-100 10x10 ml
EUR 489.6

HER2 multi peptide, (776-790,927-941,1116-1180); vaccine candidate

HER2-MP2 5 mg
EUR 781.2

HER2 multi peptide, (42-56,98-114,328-345); vaccine candidate

HER2-MP3 5 mg
EUR 634.8

Yellow Fever Vaccine Serum: 12-Month (IgG) Bleed

SER71209-1000 1ml
EUR 542.2

Yellow Fever Vaccine Serum: 12-Month (IgG) Bleed

SER71209-500 0.5ml
EUR 354.66

Incomplete Freund?s Adjuvant (IFA);vaccine adjuvant

AV-3015-10 10 ml
EUR 343.2

Incomplete Freund?s Adjuvant (IFA);vaccine adjuvant

AV-3015-100 10x10 ml
EUR 489.6

Labcold 543L Pharmacy and Vaccine Refrigerator - EACH

RLDF1819 EACH
EUR 5201.55

Recombinant CDV H Protein (aa 1-607) (strain Convac vaccine)

VAng-Lsx04670-inquire inquire Ask for price
Description: Canine distemper virus (strain Convac vaccine) Hemagglutinin glycoprotein, recombinant protein.

HER2 multi peptide, (369-386, 688-703,971-984); vaccine candidate

HER2-MP1 5 mg
EUR 634.8

Rabbit Anti-Bordetella bronchiseptica vaccine antiserum

BBV11-S 100 ug
EUR 562.8

VacciGel Direct ELISA for the measurement of Hepatitis B Vaccine (HBsAg) formulated in Alum, 48 tests, Quantitative

VAC-HBS-50 1 Kit
EUR 927.6

Yellow Fever Virus Vaccine Serum: 2 Week (IgM) Bleed

SER71201-1000 1ml
EUR 542.2

Yellow Fever Virus Vaccine Serum: 2 Week (IgM) Bleed

SER71201-500 0.5ml
EUR 354.66

Yellow Fever Virus Vaccine Serum: 6 Week (IgG) Bleed

SER71202-100 0.1ml
EUR 315.25

Yellow Fever Virus Vaccine Serum: 6 Week (IgG) Bleed

SER71202-1000 1ml
EUR 542.2

Yellow Fever Virus Vaccine Serum: 6 Week (IgG) Bleed

SER71202-500 0.5ml
EUR 354.66

ID-VAC VacciGel Direct ELISA for the identification of Hepatitis B Vaccine (HBsAg) formulated in Alum, 24 tests

VAC-HBS-VID-24 1 Kit
EUR 634.8

ID-VAC VacciGel Direct ELISA for the identification of Tetanus Toxoid Vaccine (TTX) formulated in Alum, 24 tests

VAC-TTX-VID-24 1 Kit
EUR 634.8

Vaccinia virus Complement control protein C3 (VACWR025)

1-CSB-YP302389VAI
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Vaccinia virus Complement control protein C3(VACWR025) expressed in Yeast

Tetanus Toxoid from C. tetani purified, vaccine grade

AV-9105-25 25 ug
EUR 489.6

NATtrol Flu Verification Panel (7 X 0.5 mL)

NATFVP-NNS 7 X 0.5 mL
EUR 417

Purified Exotoxin A from P. aeruginosa, vaccine grade

AV-9150-10 100 ug
EUR 416.4

TDB (Trehalose-6,6-dibehenate) Synthetic vaccine adjuvant

AV-9015-2 2 mg
EUR 489.6

Yellow Fever Virus Vaccine Serum: 6-month (IgG) bleed

SER71206-1000 1ml
EUR 542.2

Yellow Fever Virus Vaccine Serum: 6-month (IgG) bleed

SER71206-500 0.5ml
EUR 354.66

ID-VAC VacciGel Direct ELISA for the identification of Diphtheria Toxoid Vaccine (DTX) formulated in Alum, 24 tests

VAC-DTX-VID-24 1 Kit
EUR 634.8

Japanese Encephalitis Vaccine Serum: 6-Month (IgG) Bleed

SER71210-1000 1ml
EUR 542.2

Japanese Encephalitis Vaccine Serum: 6-Month (IgG) Bleed

SER71210-500 0.5ml
EUR 354.66

Squalene (oil-in-water nano emulsion);vaccine adjuvant

AV-3020-10 10 ml
EUR 343.2

Yellow Fever Virus Vaccine Serum: Pre-Vaccination Bleed

SER71200-100 0.1ml
EUR 315.25

Yellow Fever Virus Vaccine Serum: Pre-Vaccination Bleed

SER71200-1000 1ml
EUR 542.2

Yellow Fever Virus Vaccine Serum: Pre-Vaccination Bleed

SER71200-500 0.5ml
EUR 354.66

Lipopolysaccharides (LPS) (Salmonella typhimurium) vaccine adjuvant

AV-7020-1 1 mg
EUR 196.8

Lipopolysaccharides (LPS) (Salmonella typhimurium) vaccine adjuvant

AV-7020-10 10 mg
EUR 634.8

Purified Pasteurella multocida Toxin (146 kda), vaccine grade

AV-9145-10 10 ug
EUR 416.4

ID-VAC VacciGel Direct ELISA for the identification of B. Pertussis Toxoid Vaccine (PTX) formulated in Alum, 24 tests

VAC-PTX-VID-24 1 Kit
EUR 634.8

Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant

AV-7015-1 1 mg
EUR 196.8

Lipopolysaccharides (LPS) (Escherichia coli 0111:B4) vaccine adjuvant

AV-7015-10 10 mg
EUR 634.8

L.J.Slopes for BCG Vaccines

SL179-50NO 1 unit
EUR 156.96
Description: L.J.Slopes for BCG Vaccines

Purified CRM197 (Diphtheria Toxin mutant) protein vaccine grade

AV-9125-100 100 ug
EUR 416.4

QS-21 (Quillaja saponaria), Vaccine adjuvant, (EU GMP grade) >95%

AV-4010-1 1 mg
EUR 489.6

QS-21 (Quillaja saponaria), Vaccine adjuvant, (EU GMP grade) >95%

AV-4010-5 5 mg
EUR 1951.2

Japanese Encephalitis Virus Vaccine Serum: Pre-Vaccination Bleed

SER71207-100 0.1ml
EUR 315.25

Japanese Encephalitis Virus Vaccine Serum: Pre-Vaccination Bleed

SER71207-1000 1ml
EUR 542.2

Japanese Encephalitis Virus Vaccine Serum: Pre-Vaccination Bleed

SER71207-500 0.5ml
EUR 542.2

Recombinant Vaccinia virus Complement control protein C3 (VACWR025)

CSB-YP302389VAI 6104 mg Ask for price

Recombinant Vaccinia virus Complement control protein C3(VACWR025)

AP74192 1mg
EUR 3389

ID-VAC Human Anti-Influenza B Vaccine ELISA kit, 24 tests

920-FLB-VID-24 1 Kit
EUR 634.8

Vaccigel Alum adjuvant (2% Aluminum hydroxide, ready to use), Vaccine adjuvant

AV-1010-50 50 ml
EUR 343.2

Monophosphoryl lipid A (MPLA) (Synthetic, TLR4/Th1) vaccine adjuvant

AV-7030-1 1 mg
EUR 489.6

Monophosphoryl lipid A (MPLA) (Synthetic, TLR4/Th1) vaccine adjuvant

AV-7030-5 5 mg
EUR 1365.6

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Schistosoma mansoni vaccine (Smp-80/GST) by ELISA

960-190-CUX Custom Ask for price

NATtrol Respiratory Panel 2 (RP2) Controls (Ea)

NATRPC2-BIO Ea
EUR 550.46
Description: Please contact Gentaur in order to receive the datasheet of the product.

Diphtheria Toxoid/Toxin (DTX) Vaccine ELISA for the measurement DTX in biological buffer, 96 tests, quantitative

940-DTX-AG1 1 Kit
EUR 1448.4

Vaccigel Alum adjuvant adsorbed with Ovalbumin (OVA @1 mg/ml), Vaccine adjuvant

AV-1010-OVA 1 ml
EUR 270

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Yellow Fever Virus (YFV) vaccine (ENV/prM/NS1) by ELISA

530-200-CUX Custom Ask for price

Vaccigel AlumPhos adjuvant (2% Aluminum phosphate, ready to use), Vaccine adjuvant

AV-1015-50 50 ml
EUR 270

Saponins vaccine adjuvant Combo Pak-1 (contains 1mg of QS21,100 mg of Vet-SAP and 1 g of Saponin).

AV-4000-PK-1 1 pk
EUR 634.8

HER2 peptide, (776 ? 790 fused with LRMK, C-Term ), GP2 vaccine candidate

HER2-776-P 5 mg
EUR 343.2

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Varicella Zoster Virus (VZV/chickenpox) vaccine by ELISA

520-200-CUX Custom Ask for price

Rabbit Anti-HER2 peptide IgG (cyclic 597-626 vaccine candidate) Aff pure

HER2-597-A 100 ul
EUR 578.4

Monophosphoryl lipid A (MPLA)-SM (S. enterica Minnesota, 595),vaccine adjuvant

AV-7025-5 5 mg
EUR 1886.4

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Respiratory syncytial virus (RSV) vaccine (RSV-F) by ELISA

510-190-CUX Custom Ask for price

ID-VAC Human Influenza A Vaccine identification ELISA kit, 24 tests

920-FLA-VID-24 1 Kit
EUR 634.8

HER2 peptide, cyclic, (563-598, cys-cys disulphide bond); vaccine candidate

HER2-563-P 5 mg
EUR 562.8

HER2 peptide, cyclic, (585-598, cys-cys disulphide bond); vaccine candidate

HER2-585-P 5 mg
EUR 416.4

HER2 peptide, cyclic, (597-626, cys-cys disulphide bond) vaccine candidate

HER2-597-P 5 mg
EUR 489.6

HER2 peptide, cyclic, (613-626, cys-cys disulphide bond); vaccine candidate

HER2-613-P 5 mg
EUR 416.4

Single Donor Human SARS-CoV-2 Positive With Vaccine Positive Serum

ISERSCOV2VPP each
EUR 209
Description: Single Donor Human SARS-CoV-2 Positive With Vaccine Positive Serum

Single Donor Human SARS-CoV-2 Positive With Vaccine Positive Plasma

IPLASCOV2VPP each
EUR 209
Description: Single Donor Human SARS-CoV-2 Positive With Vaccine Positive Plasma

Vaccigel Alum adjuvant adsorbed with Lipopolysaccharide (LPS @1 mg/ml), Vaccine adjuvant

AV-1010-LPS 1 ml
EUR 489.6

Rabbit Anti-West Nile Virus (WNV vaccine/Innovator, inactivated) antiserum

WNV12-S 100 ul
EUR 548.4

EZ‐PRRSV/Flu A Control Set

TC-9089-096 each
EUR 90

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to Meninigitis B Vaccine Proteins (NadA/fHBP/NHBA/PorA) by ELISA

600-900-CUX Custom Ask for price

NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL)

NATRPC2.1-BIO 12 x 0.3mL
EUR 529

Custom Testing of Samples for Antibodies (IgA/IgG/IgM) to B. pertussis vaccine (Toxin/Toxoid/LPS/FHA/PRN/Fim2/3) by ELISA

960-100-CUX Custom Ask for price

Monophosphoryl lipid A (MPLA)-SM (S. enterica Minnesota, R595),vaccine adjuvant

AV-7025-1 1 mg
EUR 562.8

Vaccigel Alum adjuvant adsorbed with Bovine Serum Albumin (BSA @1 mg/ml), Vaccine adjuvant

AV-1010-BSA 1 ml
EUR 343.2

Rabbit Anti-HER2 peptide IgG (cyclic 367-37; E75 vaccine candidate) Aff pure

HER2-369-A 100 ul
EUR 578.4

Human Anti-Her2 vaccine (E75-peptide) IgG ELISA kit, 96 tests, Quantitative

200-640-HRH 1 Kit
EUR 927.6

Human Anti-Her2 vaccine (E75-peptide) IgM ELISA kit, 96 tests, Quantitative

200-650-HRM 1 Kit
EUR 927.6

Mouse Anti-Her2 vaccine (E75-peptide) IgG ELISA kit, 96 tests, Quantitative

200-660-HRH 1 Kit
EUR 927.6

Mouse Anti-Her2 vaccine (AE37-peptide) IgM ELISA kit, 96 tests, Quantitative

200-670-HRM 1 Kit
EUR 927.6

Human Anti-Her2 vaccine (AE37-peptide) IgG ELISA kit, 96 tests, Quantitative

200-700-HRH 1 Kit
EUR 927.6

Human Anti-Her2 vaccine (AE37-peptide) IgM ELISA kit, 96 tests, Quantitative

200-710-HRM 1 Kit
EUR 927.6

Mouse Anti-Her2 vaccine (AE37-peptide) IgG ELISA kit, 96 tests, Quantitative

200-720-HRH 1 Kit
EUR 927.6

Mouse Anti-Her2 vaccine (AE37-peptide) IgM ELISA kit, 96 tests, Quantitative

200-730-HRM 1 Kit
EUR 927.6

Frank Green